A trans woman cannot currently become pregnant or carry a child. No uterine transplant has ever been performed in a trans woman, and no other procedure exists that would make pregnancy possible in someone born without a uterus, ovaries, and the broader reproductive anatomy needed to sustain a fetus. That said, the science is not standing still, and there are real pathways to biological parenthood that trans women can pursue right now.
Why Pregnancy Isn’t Possible Today
Carrying a pregnancy requires far more than a uterus. The body needs a blood supply robust enough to nourish a growing placenta, a hormonally responsive uterine lining that thickens and sheds on a cycle, ligaments and connective tissue to anchor the uterus in the pelvis, and a functioning cervix and vagina for delivery. Trans women, even after gender-affirming surgery, do not have any of these structures. A neovagina created from penile skin during surgery is anatomically different from a natal vagina and lacks the mucosal lining that would need to connect to a transplanted uterus.
Some people point to abdominal pregnancies, where a fertilized egg implants outside the uterus in the abdominal cavity, as evidence that a uterus isn’t strictly necessary. This comparison doesn’t hold up. Abdominal pregnancies are medical emergencies with a maternal death rate between 1 and 18 percent and fetal mortality between 40 and 90 percent. Surviving babies have birth defects in about 21 percent of cases. These pregnancies happen by accident and are treated as life-threatening, not as a model for reproduction.
The Uterine Transplant Question
Uterine transplantation has worked in cisgender women. More than 42 procedures have been performed worldwide, resulting in at least 12 live births, all in women who were born with a uterus that was absent or nonfunctional. These successes have fueled speculation about whether the same surgery could be adapted for trans women.
A 2019 review in BJOG, a major obstetrics journal, concluded that “there is no overwhelming clinical argument against performing” uterine transplantation in trans women, but the practical barriers are significant. The transplant would need to include the uterus, cervix, a section of vaginal tissue, surrounding ligaments, and the major blood vessels that feed it. Because a trans woman’s surgically created vagina wouldn’t connect properly to a donor uterus, surgeons would likely need to transplant the donor vagina along with the uterus in a single block. That means the organ could only come from a deceased donor, not a living one.
Anchoring the uterus in a pelvis that never developed the ligaments meant to hold one presents another challenge. Surgeons would need to retrieve extra ligament tissue from the donor and attach it to structures in the recipient’s pelvis that weren’t designed for this purpose. The vascular anatomy adds complexity too: the internal iliac vein, which would supply blood to the transplanted uterus, varies considerably from person to person in its position and branching pattern.
Giuliano Testa, a transplant surgeon at Baylor University Medical Center who has directed uterine transplant programs, has said that hormones would likely be the biggest obstacle. A trans woman would need a carefully managed hormonal environment to support a pregnancy, including progesterone supplementation to maintain the uterine lining and prevent dangerous overgrowth. None of this has been tested in animal models, let alone in humans. Cadaver studies to assess basic surgical feasibility have been recommended as a necessary first step before any clinical attempt.
How Hormone Therapy Affects Fertility
Estrogen-based hormone therapy suppresses sperm production, and most trans women on hormones are not producing mature sperm by the time they undergo gender-affirming surgery. But this effect is not always permanent. A study tracking nine trans women who stopped hormone therapy found that all of them eventually recovered viable sperm production. The timeline ranged widely: some had sperm present within three months, while one required a surgical extraction procedure at 17 months. There was no clear link between how long someone had been on hormones and how quickly fertility returned.
Of four trans women in that study who stopped hormones specifically to conceive with a partner, three succeeded, though the time to conception varied from 4 to 40 months. Stopping hormone therapy can cause significant distress, since the physical changes of feminization partially reverse, so this route involves real tradeoffs.
Fertility Preservation Before Transition
Both the World Professional Association for Transgender Health (WPATH) and the Endocrine Society recommend that all transgender individuals receive counseling about how treatment affects fertility and what preservation options exist before starting medical transition. The American Society for Reproductive Medicine echoes this, extending the recommendation to postpubertal minors as well.
For trans women, the most straightforward option is sperm banking. A sample is collected, analyzed, frozen, and stored for potential use years or even decades later through in vitro fertilization or intrauterine insemination with a partner or surrogate. The initial collection and freezing costs vary by clinic, but annual storage fees typically range from $100 to $500. Some insurance plans cover part of this, though many do not.
Banking sperm before starting hormones gives the best chance of a high-quality sample, but it’s worth knowing that some recovery of sperm production is possible even after years of hormone use, as the research above shows.
Paths to Biological Parenthood Right Now
While carrying a pregnancy personally is not an option today, trans women do have real avenues to become biological parents. Using banked or recovered sperm, a trans woman can have a genetically related child through a partner who can carry a pregnancy or through gestational surrogacy, where an embryo created via IVF is carried by a surrogate. The child shares the trans woman’s DNA in the same way it would in any sperm-based conception.
Experimental Technology on the Horizon
A technology called in vitro gametogenesis (IVG) aims to create functional eggs or sperm from ordinary body cells like skin or blood cells. If it works, it could theoretically allow a trans woman to produce eggs from her own cells, removing the need for a sperm sample entirely and opening the possibility of genetic motherhood in a more complete sense. Forecasters in the field predict the first baby conceived through IVG is roughly a decade away, but researchers involved describe the possibilities for transgender people as “theoretic” at this stage. Regulatory barriers in the United States are significant: federal law prohibits funding human embryo research, and separate rules restrict the FDA from reviewing clinical trials involving heritable genetic modifications, which IVG may fall under.
Safety is the central concern. Because IVG involves creating reproductive cells from scratch, any genetic or epigenetic errors introduced in the process could be passed to future generations. Clinicians have emphasized that proving the technique is safe for resulting children will take priority over speed.